How a Cal­i­for­nia biotech briefly tripled its val­ue by hyp­ing a Covid-19 ‘cure’

Last week, a Cal­i­for­nia biotech called Sor­ren­to Ther­a­peu­tics emailed re­porters about the dis­cov­ery of an “ex­cep­tion­al­ly po­tent an­ti­body” for Covid-19. Then the CEO, Hen­ry Ji …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER